@acammarota.bsky.social presenting her work on clinical predictors and molecular architecture of #TLS in #CCA 🔬at @easlnews.bsky.social #LiverCancerSummit in Edinburgh.
Great job! 👏🏻👏🏻👏🏻
#AnaLleo #HumanitasUniversity #Humanitas
Research on #biliary tract #cancer (#BTC) is advancing rapidly. However, the delivery of these advances to patients is lagging behind, new studies co-led by @uofglasgow.bsky.social, @usaloficial.bsky.social and the IRCCS Humanitas Research Hospital of Milan, presented at the #LiverCancerSummit find.
From February 20th to 22nd, members of DiCE attended the
@easlnews.bsky.social #LiverCancerSummit in Paris 🇫🇷. We left with several new ideas and inspiration to continue collaborating with all stakeholders to improve liver cancer patient outcomes.
La catedrática Rocío I.R. Macías
🔬 La catedrática Rocío I.R. Macías, coautora del estudio, presenta este trabajo en el EASL #LiverCancerSummit, principal evento sobre investigación y práctica del cáncer de hígado.
Este proyecto puede impulsar un mayor acceso a terapias potencialmente más eficaces y mejoras en la atención médica. 🥼
Ending on a high note with an all time favorite, polvo àlagareiro. Goodbye estoril and thank you for the hospitality (and the tentacles) #LiverCancerSummit
IO combos, adoptive T Cell therapies and more innovative therapies being tested for #HCC and Bile duct cancer. Hopefully more options in the clinic soon. @LorenzaRimassa @TimGreten #LiverCancerSummit @EASLedu
Factors that lead to #sarcopenia in cancer include
👤direct toxic effect of chemotherapy
👤hypothalamic-pituitary axis suppression
👤bed rest and lack of activity
@EASLedu #LiverCancerSummit
Important topic of cancer cachexia being discussed @EASLedu #livercancersummit
✅loss of >5% total body wt over 6 months or less
✅occurs in up to 40% cancer patients
✅systemic inflammatory condition
✅reversible with response to therapy
✅starts early so intervene early
Great panel on multidisciplinary care of #HCC encompassing logistics, proposed testing in different resource settings and psychooncology @EASLedu #livercancersummit
I will admit. I have come around when it comes to SBRT for local control of #HCC. Does have a role in selected patients @EASLedu #livercancersummit
Prof Mazzaferro:
“Downstaging is reduction of viable tumor burden and not debulking”
Important and often misunderstood concept.
#LiverCancerSummit @EASLedu
Prof. Vincenzo Mazzaferro of Milan criteria fame goes back to the well. The yin and the yang of liver transplantation for #HCC: expansion vs. downstaging @EASLedu #LiverCancerSummit
Q&A Prof. Torbenson: serum B12 level may be useful to monitor for recurrence of fibrolamellar #HCC but can a also be high with garden variety HCC (I didn’t know that!) #LiverCancerSummit @EASLedu
“Rare” liver tumor session with Profs. Roskams, Torbenson, @HurstMajno @Zucmanrossi @valerie_paradis
(Uncommon rather than rare) #LiverCancerSummit @EASLedu
@Zucmanrossi covers the spectrum of hepatocellular malignancies from cradle (hepatoblastoma) to grave (#HCC) apparently less than 10 fibrolamellar HCC/year in France (seems very low) @EASLedu #LiverCancerSummit
Great debate on all things systemic therapy, molecular profiling and new CCA targets including claudin1-Ab mAb @LorenzaRimassa @curecc @EASLedu #LiverCancerSummit
Q&A brings up the issue of 1L rx of CCA if driver mutations identified. Panel suggests we need more data before using targeted therapies in this setting. If MSI-high could consider #pembrolizumab given tumor agnostic indication @DrHarryDOesHep @EASLedu #LiverCancerSummit @curecc
Interesting debate regarding timing of molecular profiling of iCCA and how actionable it is? Do you test at the time of surgery? Recurrence? Both? and would you use the information in the adjuvant setting? Many questions. Few answers. @EASLedu #LiverCancerSummit
When in Lisboa, I always go for some seafood especially octopus washed down with some cerveja tulipa! (I am not a bacalau or Portuguese custard tart fan sadly) #LiverCancerSummit @EASLnews
The sights and smells of Mercado de la ribeira! Back to its pre covid hustle and bustle @EASLnews @EASLedu #LiverCancerSummit
@EASLedu @ILCAnews Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma @JHepatology published online yesterday #livercancersummit www.journal-of-hepatology.eu/article/S0168-8278(23)00...
Prof. Tim Meyer @ucl presents a useful summary of studies reporting on the accuracy of LI-RADS: 5 is essentially #HCC 4 is HCC 3/4 of the time and then it gets murky. LI-RADS concept applies to cirrhosis, #HBV and existing dx HCC @EASLedu @EASLnews #LiverCancerSummit
1L systemic therapy for iCCA should be gem/cis plus #durvalumab where available per @EASLedu @ILCAnews
iCCA guidelines. Other targeted therapies depending on molecular profiling apply #LiverCancerSummit @curecc
Cholangiocarcinoma @EASLedu @ILCAnews clinical practice guidelines being presented by Profs. Alvaro & Sangro. Contributors incl. experts @ma5RN @sapisochin and patient advocates @curecc #LiverCancerSummit @EASLnews
Vigorous discussion regarding testing for the purposes of screening, surveillance and metastatic work up for #HCC @docamitgs @tom_luedde @JordiRimola
No takers for PET under any circumstance. Contrast enhanced ultrasound (CEU) promising #LiverCancerSummit
Too early for #GI23 but adjuvant #HCC rx should have dedicated sessions @HccTagConf, @EASLnews #livercancersummit & @ILCAnews . @augustoNYC @LorenzaRimassa @AnjanaPillaiMD @DrElkhoueiry @ArndtVogel @MarkYarchoan @ma5RN @Zucmanrossi @ArndtVogel @sapisochin @riadsalemIR @bruixj
